167 related articles for article (PubMed ID: 34719056)
1. Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients.
Wille K; Huenerbein K; Jagenberg E; Sadjadian P; Becker T; Kolatzki V; Meixner R; Marchi H; Fuchs C; Griesshammer M
Eur J Haematol; 2022 Feb; 108(2):154-162. PubMed ID: 34719056
[TBL] [Abstract][Full Text] [Related]
2. Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort.
Kander EM; Raza S; Zhou Z; Gao J; Zakarija A; McMahon BJ; Stein BL
Int J Hematol; 2015 Nov; 102(5):587-93. PubMed ID: 26440973
[TBL] [Abstract][Full Text] [Related]
3. High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation.
Wille K; Sadjadian P; Becker T; Kolatzki V; Horstmann A; Fuchs C; Griesshammer M
Ann Hematol; 2019 Jan; 98(1):93-100. PubMed ID: 30155552
[TBL] [Abstract][Full Text] [Related]
4. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.
Kaifie A; Kirschner M; Wolf D; Maintz C; Hänel M; Gattermann N; Gökkurt E; Platzbecker U; Hollburg W; Göthert JR; Parmentier S; Lang F; Hansen R; Isfort S; Schmitt K; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
J Hematol Oncol; 2016 Mar; 9():18. PubMed ID: 26944254
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH).
Appelmann I; Kreher S; Parmentier S; Wolf HH; Bisping G; Kirschner M; Bergmann F; Schilling K; Brümmendorf TH; Petrides PE; Tiede A; Matzdorff A; Griesshammer M; Riess H; Koschmieder S
Ann Hematol; 2016 Apr; 95(5):707-18. PubMed ID: 26916570
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.
Rungjirajittranon T; Owattanapanich W; Ungprasert P; Siritanaratkul N; Ruchutrakool T
BMC Cancer; 2019 Feb; 19(1):184. PubMed ID: 30819138
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Molecular Attributes of Patients With BCR/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges.
Singh S; Kaur K; Paul D; Jain K; Singh J; Narang V; Garg B; Sood N; Dhillon B
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e569-e578. PubMed ID: 33757770
[TBL] [Abstract][Full Text] [Related]
8. Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.
Krahling T; Balassa K; Kiss KP; Bors A; Batai A; Halm G; Egyed M; Fekete S; Remenyi P; Masszi T; Tordai A; Andrikovics H
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):98-104. PubMed ID: 26487696
[TBL] [Abstract][Full Text] [Related]
9. Management and Outcome of Venous Thrombosis in Patients with Myeloproliferative Neoplasms: Data from the Israeli MPN Working Group.
Gutwein O; Lavi N; Barzilai M; Shacham-Abulafia A; Leader A; Chubar E; Dally N; Shapira S; Mishchenko E; Ellis M; Koren-Michowitz M
Acta Haematol; 2021; 144(4):438-445. PubMed ID: 33316809
[TBL] [Abstract][Full Text] [Related]
10. High Level of Circulating Microparticles in Patients with BCR/ABL Negative Myeloproliferative Neoplasm - a Pilot Study.
Aswad MH; Kissová J; Rihova L; Zavrelova J; Ovesná P; Penka M
Klin Onkol; 2019; 32(2):109-116. PubMed ID: 30995850
[TBL] [Abstract][Full Text] [Related]
11. Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms.
Kim J; Byun JM; Hong J; Koh Y; Shin DY; Kim I; Yoon SS; Park H; Bang SM
Sci Rep; 2021 Sep; 11(1):17819. PubMed ID: 34497309
[TBL] [Abstract][Full Text] [Related]
12. Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms.
Seguro FS; Teixeira LLC; da Rosa LI; da Silva WF; Nardinelli L; Bendit I; Rocha V
J Thromb Thrombolysis; 2020 May; 49(4):667-672. PubMed ID: 31898273
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms.
Hoekstra J; Bresser EL; Smalberg JH; Spaander MC; Leebeek FW; Janssen HL
J Thromb Haemost; 2011 Nov; 9(11):2208-14. PubMed ID: 22040061
[TBL] [Abstract][Full Text] [Related]
14. [Clinical Analysis of 208 Patiets with BCR/ABL Negative Myeloproliferative Neoplasms].
Shen QH; Guo YJ; Xue CE; Wang Y; Lin FR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):159-164. PubMed ID: 30738463
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms.
Guy A; Poisson J; James C
Leukemia; 2021 Apr; 35(4):935-955. PubMed ID: 33658660
[TBL] [Abstract][Full Text] [Related]
16. Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms.
Kissova J; Bulikova A; Ovesna P; Bourkova L; Penka M
Int J Hematol; 2014 Nov; 100(5):429-36. PubMed ID: 25227185
[TBL] [Abstract][Full Text] [Related]
17. The impact of CYP2D6*4 and GSTP1 Ile105Val polymorphisms on the susceptibility to develop BCR-ABL1 negative myeloproliferative neoplasms.
Daglar-Aday A; Akadam-Teker B; Yonal-Hindilerden I; Dermenci H; Sahin E; Hindilerden F; Yilmaz-Aydogan H; Ozturk O; Yavuz AS
Mol Biol Rep; 2020 Oct; 47(10):7413-7420. PubMed ID: 32918123
[TBL] [Abstract][Full Text] [Related]
18. Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study.
Baek SW; Moon JY; Ryu H; Choi YS; Song IC; Lee HJ; Yun HJ; Kim S; Jo DY
Korean J Intern Med; 2018 Jul; 33(4):790-797. PubMed ID: 28298076
[TBL] [Abstract][Full Text] [Related]
19. Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic.
Barbui T; De Stefano V
Curr Hematol Malig Rep; 2021 Oct; 16(5):455-463. PubMed ID: 34586561
[TBL] [Abstract][Full Text] [Related]
20. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.
Martinelli I; De Stefano V; Carobbio A; Randi ML; Santarossa C; Rambaldi A; Finazzi MC; Cervantes F; Arellano-Rodrigo E; Rupoli S; Canafoglia L; Tieghi A; Facchini L; Betti S; Vannucchi AM; Pieri L; Cacciola R; Cacciola E; Cortelezzi A; Iurlo A; Pogliani EM; Elli EM; Spadea A; Barbui T
Am J Hematol; 2014 Nov; 89(11):E200-5. PubMed ID: 25042466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
